Facebook Twitter LinkedIn Google Plus RSS

Covance earnings rise in Q2

By ,

Princeton-based drug developer Covance announced Tuesday its fiscal second-quarter results rose from the same period in 2013.

Covance said in a news release that pro forma earnings were 95 cents per diluted share, an increase of 21.5 percent from the year-ago period. Net revenue reached $639 million, up 8 percent from the year before.

"In the second quarter, a stronger-than-expected performance in early development and continued strong growth in central laboratories more than offset lower-than-expected growth in clinical development," Joe Herring, chairman and CEO, said in the release.


Space in the right place: Hartz suddenly has huge office inventory in North Jersey

New leader at RWJ Foundation is a man on a mission

Profiles of success: New Jersey's young entrepreneurs

More From This Industry

Eric Strauss

Eric Strauss

Eric Strauss is the digital content editor for NJBIZ. He has been a reporter and editor for newspapers in New Jersey and Pennsylvania, as well as for a number of websites. You can contact him at erics@njbiz.com.

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy